Form 4: 10x Genomics Director Sarah A. Teichmann Reports Acquisition of Class A Common Stock

Director Sarah A. Teichmann reports the acquisition of 19,002 shares of 10x Genomics Class A Common Stock in a transaction dated August 30, 2024.

Summary

• On August 30, 2024, Sarah A. Teichmann, a director of 10x Genomics, Inc. [TXG], acquired 19,002 shares of Class A Common Stock.
• The shares were acquired through restricted stock units (RSUs).
• Each RSU represents a contingent right to receive one share of Class A Common Stock upon vesting.
• 1/3rd of the RSUs shall vest on November 21, 2025 and 1/12th of the RSUs shall vest on each quarterly anniversary thereafter for the following two years, subject to the Reporting Person continuing as a service provider through each such date.
• Following the transaction, Teichmann directly owns 19,002 shares of Class A Common Stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. Insider buying is generally viewed favorably, suggesting confidence in the company's prospects. The vesting schedule indicates a long-term commitment.

Positives

• The acquisition of shares by a director signals confidence in the company's future prospects.

Future Outlook

The vesting schedule of the RSUs extends over two years, indicating a long-term commitment from the director.

Industry Context

Insider transactions are closely monitored as they can provide insights into a company's performance and future prospects relative to its peers in the genomics industry.

Stakeholder Impact

• Shareholders may view the director's acquisition of shares as a positive signal.
• Employees may see this as a sign of confidence in the company's future.

Key Dates